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The use of antiretroviral therapy as prevention in highly HIV-exposed populations has proven to be 
effective in protecting against HIV infection in several studies. The Partners PrEP study 
demonstrated the safety and efficacy of oral tenofovir disoproxyl fumarate (Viread®) alone or in 
combination with emtricitabine (Truvada®), both inhibitors of HIV reverse transcriptase, as compared 
to placebo. These drugs were tested in almost 5,000 serodiscordant couples from Kenya and 
Uganda. While a high protection rate was shown, a concern has been raised that the use of 
treatment as prevention could induce selection for resistant strains of HIV. 
To address this problem, Dr. Dara Lehman from the Human Biology Division at Fred Hutch applied a 
very sensitive method to detect resistance-linked mutations in all subjects who seroconverted during 
the study or were acutely infected at the time of study randomization. A total of 122 HIV 
seroconversions occurred during the study, of which 18 were determined to be acute seronegative 
HIV infections at study enrollment. The median time between the estimated date of HIV infection and 
drug discontinuation, when the presence of the drug together with the virus could select for resistant 
strains, was 45 days. Mutations associated with resistance to the PrEP drugs were detectable in 
19% of seroconverted subjects, but in the majority of these cases resistance mutations were present 
only at a very low frequency, less than 1% of an individual's viral population. Since resistance at 
<1% has not previously been associated with increased risk of treatment failure, this frequency was 
used as a cutoff for the study. Five seroconverters had one or more mutations associated with their 
PrEP regimen at a level higher than 1%: three were individuals with unrecognized acute infection at 
the time of PrEP randomization, and only two were subjects that became infected during the trial and 
had evidence of PrEP use during HIV infection. 
To answer the question of whether PrEP might induce resistance in those who become infected 
despite its use is imperative at this time, as the FDA recently approved PrEP use outside of clinical 
trials, where the time between HIV tests is likely to be longer than the monthly testing that occurred 
during the clinical trials. Thus, in those that become infected, the coinciding presence of the drug 
and the virus together is likely to be longer. The data reveal that resistance to PrEP is an unlikely 
event in subjects receiving it as prophylaxis, but can occur both in unrecognized acute infections as 
well as in breakthrough infections, and more frequently when the combination of tenofovir and 
emtricitabine is used. The frequency of mutations leading to resistance is lower than previously 
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calculated with mathematical models, and, together with the data proving a low frequency of 
seroconversion in PrEP users, this study supports the safety of PrEP use in situations of high 
exposure. The conclusions of the study are summarized in Dr. Lehman's words: " The small risk of 
resistance must be balanced with the high number of infections averted by PrEP use, a prevention 
strategy safe and efficacious for situations of high exposure to HIV."   
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Figure provided Dr. Dara Lehman. 
Frequency resistance-linked mutations in seroconverters with PrEP drugs detected 
during or after HIV acquisition. Higher levels are shown in darker blue colors. 
FTC/TDF, emtricitabine plus tenofovir disoproxil fumarate; TDF, tenofovir 
disoproxil fumarate alone. 
 
